MedPath

Comparison the efficacy of Attentalin and Atomoxetin in ADHD

Phase 3
Conditions
Attention deficit and hyperactivity disorder.
Attention-deficit hyperactivity disorders
Registration Number
IRCT20230419057960N1
Lead Sponsor
Hamedan University of Medical Sciences
Brief Summary

Not available

Detailed Description

Not available

Recruitment & Eligibility

Status
Pending
Sex
All
Target Recruitment
46
Inclusion Criteria

Patients who recieved Attentin Deficite and Hyoeractivity Disorder due to DSM 5 criteria .
Obtaining Informed consent from parents
Age 6 to 12 years old

Exclusion Criteria

Seizures
Glaucoma
History of hyperthyroidism
Eating disorders (anorexia)
Children with a history of liver , kidney , heart diseases or other chronic illnesses requiring care
Children who have taken MAOI medication for the 15 days prior to entering the study.
substance abuse disorder

Study & Design

Study Type
interventional
Study Design
Not specified
Primary Outcome Measures
NameTimeMethod
Symptoms of hyperactivity/attention deficit. Timepoint: before the trial and 3 and 6 weeks later. Method of measurement: ADHD Rating Scale.
Secondary Outcome Measures
NameTimeMethod
© Copyright 2025. All Rights Reserved by MedPath